Which of the following drug is a treatment of osteoporosis? (AIIMS Nov 2010)
a. Raloxifene is a selective estrogen receptor modulator with estrogen agonistic action on bone and antagonistic action on breast and endometrium. It is therefore the preferred drug for the treatment and prevention of post-menopausal osteoporosis.
b. Major adverse effect of this agent is increased risk of thromboembolism.